The research, led by Bernard Mulvey, Heena R. Divecha, and colleagues at the Lieber Institute for Brain Development working with collaborators at Johns Hopkins and the University of Cambridge, applied spatially resolved transcriptomics, a technique that maps gene expression across intact tissue sections while preserving information about where each gene is active, to postmortem locus coeruleus tissue from 33 neurotypical middle-aged human brain donors. Crucially, the donors were stratified by major Alzheimer’s disease risk factors, including biological sex, African or European genetic ancestry, and apolipoprotein E haplotype, specifically carriers of the APOE E4 allele, which raises disease risk, versus carriers of the APOE E2 allele, which appears protective. This design allowed the investigators to ask a subtle but important question: do the genes expressed in and around the locus coeruleus already differ, in healthy middle age, depending on which Alzheimer’s risk variants a person carries?

The answer, in several respects, is yes, and the details are illuminating. When the researchers compared gene expression patterns across APOE haplotypes, they found reduced expression of astrocytic genes, meaning genes characteristically active in star-shaped support cells called astrocytes, in the tissue immediately surrounding locus coeruleus neurons in E4 carriers. Astrocytes are far more than passive glue; they regulate synapse formation, supply neurons with cholesterol and metabolic support, control local blood flow, buffer neurotransmitters, and respond to norepinephrine signaling from the locus coeruleus itself. A diminishment of astrocytic gene expression near these noradrenergic neurons suggests that E4 carriers may have subtly weakened local support infrastructure around one of the brain’s most Alzheimer’s-vulnerable cell populations, potentially lowering the threshold at which tau pathology or other stresses become damaging.

The study also uncovered ancestry-specific differences in locus coeruleus gene expression, a finding with real public health significance given well-documented disparities in dementia incidence and outcomes across populations. Follow-up analyses using in situ sequencing at single-cell resolution demonstrated that the APOE-related differences in regional gene expression were partly attributable to astrocytes themselves, and that the haplotype effects were more pronounced in donors of European ancestry. This interaction between genetic ancestry and APOE haplotype echoes earlier work showing that the relationship between APOE E4 and Alzheimer’s pathology differs across admixed populations, and it underscores the importance of including ancestrally diverse cohorts in neuroscience research rather than extrapolating from studies of predominantly European-ancestry subjects.

Perhaps the most visually and conceptually striking component of the study concerns neuromelanin, the dark pigment that gives the locus coeruleus its name, which means “blue spot” in Latin. Neuromelanin accumulates in certain catecholaminergic neurons, including the noradrenergic neurons of the locus coeruleus and the dopaminergic neurons of the substantia nigra, as a byproduct of oxidative metabolism of neurotransmitters. It is sequestered within specialized autolysosomal organelles that bind potentially toxic metals such as iron, and its loss from these neurons is a hallmark of both Alzheimer’s and Parkinson’s disease. Neuromelanin-sensitive magnetic resonance imaging has emerged as a promising biomarker, with reduced pigment signal in the locus coeruleus predicting clinical severity and future progression in Alzheimer’s patients. What has remained unclear is the precise molecular relationship between a neuron’s pigment content and its gene expression program.

To address this, the team quantified neuromelanin content directly in the tissue and related it to spatial gene expression. They found that higher APOE gene expression correlated with reduced neuromelanin, and that genes whose expression tracked with local pigment levels were enriched for aging-related biological pathways. Taking the analysis to its finest resolution, the investigators used in situ sequencing data to examine individual locus coeruleus neurons, measuring neuromelanin in each cell and validating its associations with the expression of APOE itself, genes involved in norepinephrine metabolism, and components of the autophagy machinery, the cellular recycling system that clears damaged proteins and organelles. This constellation of pigment-linked genes paints a coherent picture: neuromelanin content reflects, at the single-cell level, the interplay of neurotransmitter handling, lipid biology, and protein quality control, all processes implicated in neurodegeneration.

The significance of these findings is best appreciated against the backdrop of what is already known about the locus coeruleus in Alzheimer’s disease. Postmortem studies stretching back decades, including the classic staging work of Heiko Braak and colleagues, established that phosphorylated tau appears in locus coeruleus neurons exceptionally early, often in individuals who died with no cognitive impairment. Autopsy studies have documented substantial neuronal loss in this nucleus in mild cognitive impairment and early Alzheimer’s disease, and neuroimaging research has repeatedly linked reduced locus coeruleus integrity to tau burden, memory decline, neuropsychiatric symptoms, and sleep disruption. Animal work has shown, conversely, that noradrenergic depletion exaggerates the inflammatory response to amyloid-beta pathology, while pharmacological enhancement of norepinephrine signaling can suppress neuroinflammation. The locus coeruleus, in other words, is not merely a passive victim of Alzheimer’s pathology; its noradrenergic output actively modulates the brain’s response to it.

The new study adds two crucial molecular threads to this narrative. First, it demonstrates that Alzheimer’s genetic risk acts on the locus coeruleus ecosystem, not just on its neurons in isolation. The astrocytic deficit observed near E4-carrier neurons is particularly intriguing in light of recent evidence that norepinephrine signals through astrocytes to modulate synaptic function, and that astrocytes undergo stereotyped transcriptomic changes across the spatiotemporal progression of Alzheimer’s disease. If E4 carriers begin adulthood with less robust astrocytic support around their noradrenergic neurons, this could help explain why these neurons succumb early, and why E4 homozygosity has recently been characterized as a distinct, nearly deterministic genetic form of Alzheimer’s disease. Second, by tying neuromelanin, a biomarker measurable in living patients with specialized MRI, to concrete gene expression programs involving autophagy and catecholamine metabolism, the study strengthens the mechanistic bridge between what clinicians can image and what is happening molecularly inside vulnerable neurons.

Technically, the study represents a tour de force of modern spatial genomics applied to a notoriously difficult brain region. The locus coeruleus is small, deeply located in the dorsal pons, and densely pigmented, making it easy to miss in standard postmortem dissection and challenging to analyze with conventional bulk methods that average away spatial relationships. The team’s spatially resolved transcriptomics data captured tissue architecture at spot-level resolution, while their in situ sequencing pushed the analysis to individual cells, using the pigment itself as an additional segmentation cue to define neuromelanin-rich cellular compartments. The authors have deposited all data in public repositories and built interactive web portals, using visualization tools such as Samui and spatialLIBD, allowing any researcher to explore the spatial domain assignments, gene expression maps, and stained tissue sections, an unusually transparent approach that should accelerate follow-up work across the field.

The implications reach toward prevention and early detection. Because the donors in this study were neurotypical and middle-aged, the observed molecular differences, diminished astrocytic gene expression in E4 carriers, ancestry-dependent expression patterns, pigment-linked autophagy and norepinephrine genes, represent the brain’s baseline state before overt pathology, a snapshot of vulnerability rather than of damage. Interventions aimed at supporting astrocytic function, enhancing autophagic clearance of tau, or modulating noradrenergic tone might therefore be most effective when targeted at these early molecular states rather than at established dementia. Meanwhile, the confirmation that APOE expression itself inversely tracks neuromelanin suggests that pigment imaging could serve not only as a marker of neuronal loss but as a window into the lipid-handling pathways that connect APOE biology to neurodegeneration. As the authors conclude, Alzheimer’s risk factors appear to modulate locus coeruleus vulnerability through molecular processes intrinsic to both the noradrenergic neurons and their astrocytic partners, a reminder that the neurons that wake us, focus us, and help us remember may hold some of the earliest clues to when and how Alzheimer’s disease takes hold.

The study examined 37 patients whose psychosis began after the age of 40 and compared them with 47 healthy older adults. The participants underwent two types of PET scanning: one designed to detect amyloid plaques, a hallmark of Alzheimer’s disease, and another using QST’s florzolotau (18F) tracer to visualize tau pathology in the living brain. Tau is a structural protein that normally helps stabilize neurons, but in several neurodegenerative diseases it becomes abnormally modified, accumulates inside nerve cells and disrupts their function.

The difference between the two groups was striking. Tau PET scans were positive in approximately 65% of patients with late-onset psychosis, compared with only 15% of healthy controls. Amyloid PET positivity was also substantially higher among patients, occurring in 35% compared with 2% of controls. These results suggest that a significant proportion of people who develop hallucinations or delusions later in life may carry measurable molecular signatures of neurodegeneration, even when dementia has not yet been clearly diagnosed.

The researchers emphasize that late-onset psychosis is not a single biological condition. Patients can experience similar symptoms while having very different disease processes in the brain. Some participants showed both amyloid and tau accumulation, a pattern consistent with Alzheimer’s disease. Others had tau buildup without detectable amyloid plaques, pointing toward non-Alzheimer’s forms of tau-related neurodegeneration. This distinction is important because amyloid-negative tau pathology can occur in several other neurological disorders and may follow different clinical courses.

The brain scans also revealed that tau was not distributed uniformly across patients. In several amyloid-negative cases, accumulation was particularly evident in posterior regions, including the parietal and occipital lobes. These areas contribute to attention, visual interpretation, spatial processing, judgment and the integration of information from different parts of the brain. Disruption in these systems could help explain why some patients develop false perceptions, unusual beliefs or difficulty interpreting their surroundings.

One representative set of images showed four distinct patterns of tau deposition. The first case displayed an amyloid-positive pattern associated with Alzheimer’s disease, while the remaining cases were amyloid-negative and appeared to represent other types of tau pathology. White arrowheads in the images marked areas of abnormal tau accumulation. Together, the scans illustrate why late-onset psychosis can be difficult to classify using symptoms alone: identical hallucinations or delusions may arise from different molecular changes and different networks of affected brain regions.

The study also identified a relationship between tau burden and cognitive performance. Among patients who were amyloid-positive, greater tau accumulation in the parietal lobe was associated with poorer executive function. Executive abilities include planning, shifting attention, monitoring behavior and solving problems. Although the study does not prove that tau directly causes psychosis, the association suggests that regional neurodegeneration may influence both cognitive decline and the emergence of psychiatric symptoms.

For clinicians, the findings could eventually change how new-onset psychosis in older adults is investigated. Psychiatric assessment remains essential, but symptoms alone may not reveal whether a patient has an underlying neurodegenerative disorder. PET imaging and other biological tests could help identify Alzheimer’s-related disease, non-Alzheimer’s tau pathology or a condition without substantial protein accumulation. Earlier identification may allow patients and families to receive more appropriate counseling, monitoring and treatment, while also helping researchers design clinical trials for biologically defined groups.

The researchers caution that the results should not be interpreted as evidence that every older person with hallucinations or delusions has dementia. The sample was relatively small, and PET positivity does not automatically predict when or whether an individual will develop significant cognitive impairment. Further studies involving larger and more diverse populations will be needed to determine how tau patterns evolve over time and whether they can predict treatment response. Nevertheless, the work moves late-onset psychosis closer to the era of molecular diagnosis, suggesting that what appears to be a psychiatric mystery may, in many cases, be a visible process unfolding inside the aging brain.

Subject of Research: Tau and amyloid pathology in late-onset psychosis

Article Title: High prevalence of tau pathologies in late-onset psychosis: A PET study

News Publication Date: 2 August 2026

Web References: https://doi.org/10.1038/s41380-026-03749-3

References: Molecular Psychiatry, DOI: 10.1038/s41380-026-03749-3

Image Credits: The National Institutes for Quantum Science and Technology

Keywords: late-onset psychosis, hallucinations, delusions, tau, amyloid, Alzheimer’s disease, neurodegeneration, PET imaging, florzolotau, dementia, brain imaging, psychiatric symptoms

A team at Japan’s National Institutes for Quantum Science and Technology (QST) used a circuit-focused strategy to address this mismatch. Instead of asking only where tau is located, they asked where tau-affected regions communicate in the brain—and whether those connections help explain symptoms that appear “out of place.”

To visualize tau deposition, the researchers performed tau positron emission tomography (tau PET) in 37 people with PSP using a QST-developed tracer. Each participant’s tau-positive areas were then mapped onto a functional connectivity framework built from data collected in 100 healthy individuals, enabling the team to infer which distant cortical regions were statistically linked to tau-affected sites.

Across participants, the tau distribution varied—one hallmark of neurodegenerative heterogeneity—but the remote connectivity signal converged on a common cortical circuit. This shared network, dubbed the “PSP-tau network,” involved the prefrontal cortex, anterior cingulate cortex, anterior insula, and parietal cortex, regions central to executive control processes such as attention allocation, inhibitory regulation, and planning.

Crucially, the strength of connectivity between an individual’s tau-affected areas and the PSP-tau network tracked with the severity of frontal cognitive impairment. In contrast, tau burden confined to deep regions aligned more closely with motor symptoms, including eye movement difficulties, but did not track the same cognitive profile.

These results support a dual mechanism in PSP: local tau pathology may drive motor-related dysfunction, while remote network disruption may underlie cognitive and behavioral deficits. The study therefore reframes tau-related symptoms as emergent properties of brain communication, not simply consequences of local tissue damage.

“We began with a clinical question that could not be answered by looking only at where tau accumulates,” said QST researcher Toshiyuki Hirabayashi. The findings, he added, point to how local pathology can propagate functional effects across distributed neural circuits.

Beyond PSP, the approach could inform other tau-driven diseases. If cognitive symptoms in disorders such as Alzheimer’s disease also reflect network-level disruption, circuit mapping combined with tau imaging may help identify symptom-relevant pathways and improve prediction of disease course.

Subject of Research: People
Article Title: Remote Network for Cognitive Symptoms Derived from Tau Accumulation in Progressive Supranuclear Palsy
News Publication Date: 10-Jul-2026
Web References: https://www.science.org/doi/10.1126/sciadv.aed0348
References: 10.1126/sciadv.aed0348
Image Credits: National Institutes for Quantum Science and Technology (QST)

Keywords: progressive supranuclear palsy, PSP, tau PET, brain networks, functional connectivity, executive function, cognitive impairment, neural circuits, imaging analysis, tauopathy

Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by the progressive decline in cognitive function accompanied by the buildup of abnormal protein aggregates in the brain. For decades, two proteins—amyloid-beta and tau—have been recognized as central players. Amyloid-beta plaques accumulate extracellularly, while tau forms neurofibrillary tangles inside neurons. The spatial and temporal patterns of these aggregates have been topics of intense study, but this new research emphasizes that their distribution is not always symmetrical across the brain’s hemispheres, challenging earlier assumptions of a relatively uniform pathology.

Using advanced neuroimaging techniques coupled with postmortem histopathological analysis, the study meticulously quantified the regional burden of tau and amyloid deposition in Alzheimer’s patients. Intriguingly, the data revealed that tau pathology tends to show hemispheric asymmetry that aligns with an uneven distribution of amyloid plaques. This coupling hints at a possible causative or facilitatory relationship, where the asymmetry of amyloid deposition might drive or influence the lateralization of tau pathology. Such an insight offers a biological explanation for why patients sometimes experience lateralized symptoms, such as predominantly left- or right-hemisphere cognitive impairments.

The research team employed positron emission tomography (PET) imaging tracers specific for tau and amyloid-beta to obtain in vivo visualization of protein distribution. This allowed for longitudinal tracking and high-resolution mapping of pathological load. Additionally, immunohistochemical staining of brain tissue samples validated the imaging findings at a microscopic level. The synergy between imaging and postmortem analysis provided robust, multidimensional evidence that the asymmetry is not an artifact but a reproducible hallmark of Alzheimer’s pathology at the population level.

Further analysis indicated that the degree of hemispheric asymmetry in tau correlated positively with the asymmetry of amyloid burden. This spatial correlation was most pronounced in key regions implicated in Alzheimer’s-related cognitive decline, including the medial temporal lobe and the posterior cingulate cortex. These regions are crucial for memory processing and executive function, aligning with clinical observations where asymmetric cognitive deficits correspond with more significant pathology on the affected side.

The biological underpinnings driving this asymmetry are complex but may stem from localized vulnerabilities in neuronal circuits or differential clearance mechanisms within hemispheres. The study hypothesizes that early amyloid accumulation on one side may create a microenvironment conducive to tau propagation, possibly via transneuronal spread or disruption of proteostatic systems. Understanding these pathways at a molecular and cellular level will be critical for future therapeutic interventions aiming to halt or reverse tau spreading.

This hemispheric asymmetry has profound implications for diagnosis. Conventional methods often assume bilateral, symmetric involvement and may overlook subtler, unilateral pathology. Incorporating assessments of asymmetrical tau and amyloid deposition into clinical protocols could enhance early diagnosis, particularly in atypical cases. Moreover, it may help refine prognostic models by recognizing that lateralized pathology might predict a distinct disease trajectory or response to treatment.

From a therapeutic perspective, strategies that can specifically target and modulate asymmetric amyloid or tau pathology could revolutionize Alzheimer’s care. For example, antibody-based therapies aimed at clearing amyloid or tau could be optimized to address the dominant hemisphere first or personalized based on the asymmetry profile. Such tailored approaches could maximize efficacy and minimize side effects, marking a significant departure from the conventional “one-size-fits-all” methodology.

The findings also raise fascinating questions about the relationship between structural and functional hemispheric asymmetries in the healthy brain and the progression of Alzheimer’s disease. It’s well-established that many cognitive functions, such as language and spatial reasoning, are lateralized to one hemisphere. The study suggests that these inherent asymmetries might influence vulnerability to pathological protein deposition, potentially explaining why disease manifestations are often side-biased.

Moreover, the interdisciplinary nature of the research, bridging neuroimaging, neuropathology, and clinical neuropsychology, exemplifies the power of integrated approaches in tackling complex brain disorders. The combination of cutting-edge PET imaging tracers with detailed neuropathological validation sets a benchmark for future studies aiming to unravel the multifaceted landscape of Alzheimer’s pathology.

The implications of the study extend beyond Alzheimer’s disease alone. Asymmetric patterns of neurodegeneration have been observed in other disorders such as frontotemporal dementia and Parkinson’s disease. The methodologies and principles outlined here could be adapted to investigate these conditions, potentially uncovering shared mechanisms of hemispheric vulnerability and disease progression.

One especially provocative aspect of the study is the potential for asymmetry to serve as a biomarker for disease staging or treatment monitoring. Quantitative metrics derived from the degree of hemispheric imbalance could be developed into clinical tools that track progression more sensitively than global measures of protein burden. This would enable clinicians to detect subtle changes earlier and adjust therapeutic regimens dynamically.

The researchers emphasize that future work should focus on longitudinal studies to establish causality between asymmetric amyloid and tau deposition. Understanding whether amyloid asymmetry precedes tau lobar localization or vice versa is key to unraveling the sequence of pathological events. Such knowledge would profoundly influence the timing and targets of interventional strategies.

In conclusion, this compelling research reframes Alzheimer’s disease pathology through the lens of hemispheric asymmetry, coupling two of its most notorious protein hallmarks in a spatially and functionally meaningful way. This nuanced understanding opens new avenues for diagnosis, treatment, and ultimately, the quest to decipher the enigmatic processes driving neurodegeneration. As the field advances, embracing the brain’s natural asymmetries may unlock novel opportunities to combat Alzheimer’s more effectively than ever before.

Subject of Research: Hemispheric asymmetry in tau and amyloid-beta protein deposition in Alzheimer’s disease.

Article Title: Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease.

Article References:
Anijärv, T.E., Ossenkoppele, R., Smith, R. et al. Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease. Nat Commun 16, 8232 (2025). https://doi.org/10.1038/s41467-025-63564-2

Image Credits: AI Generated

This new study aims to delve deeper into the selective vulnerability of specific brain regions to Alzheimer’s-related damage and how that relates to tau protein accumulation. Tau is a microtubule-associated protein that is crucial for maintaining neuronal structure and function. When tau misfolds and aggregates, it disrupts cellular processes, leading to neurodegeneration. Understanding why certain types of neurons are more susceptible to tau accumulation is paramount in developing targeted therapeutic strategies.

Utilizing the Matrix Inversion and Subset Selection (MISS) technique, researchers meticulously mapped approximately 1.3 million cells within the brain, evaluating their structural and functional characteristics. This detailed methodology goes beyond identifying protein accumulation; it enables the team to compare the specific cellular makeup of the hippocampus—an area heavily involved in memory processing—with regions where tau deposition occurs. By isolating glutamatergic neurons in the hippocampus, researchers have found that these cells are particularly susceptible to the neurotoxic effects associated with tau buildup.

Pedro Maia, the lead author of the study and an assistant professor of mathematics at UTA, elucidated the significance of their findings. He explained that the strong correlation between glutamatergic neurons and tau deposits suggests that these neurons are at a heightened risk of dysfunction during Alzheimer’s progression. This critical insight highlights the need for further research focused on why tau accumulation primarily targets these specific neuronal populations, ultimately advancing our understanding of Alzheimer’s pathophysiology.

Interestingly, while some neurons are adversely affected, other cells, such as oligodendrocytes, demonstrate relative resilience to tau toxicity. Oligodendrocytes are essential for the insulation of neuronal axons, and their ability to withstand tau buildup hints at a potential protective mechanism within the brain. Understanding the functional dynamics of these resilient cells could yield valuable information for developing neuroprotective strategies aimed at mitigating cognitive decline in Alzheimer’s patients.

Moreover, the implications of this research extend beyond the immediate focus on tau proteins. The analysis suggests that the diverse cellular architecture of the brain could serve as a more reliable predictor of tau accumulation than genetic predisposition alone. This notion presents a paradigm shift in how researchers might approach Alzheimer’s disease risk assessment, prioritizing cellular characteristics over solely genetic factors.

Dr. Maia emphasized that the study showcases the valuable integration of theoretical models with empirical data. This interdisciplinary approach not only enriches our understanding of disease mechanisms but also paves the way for novel intervention strategies targeting vulnerable cell types. By identifying specific cellular and genetic profiles associated with tau buildup, future research can better tailor therapies to slow or even prevent the progression of Alzheimer’s disease.

It’s vital to recognize the profound connection between structure and function in the brain, particularly in the context of neurodegenerative diseases. The emerging insights from this groundbreaking research highlight the critical need to connect cellular composition with cognitive function. As we continue to unravel the complexities of Alzheimer’s, it becomes increasingly evident that understanding the precise interrelations of brain cells could be the key to unlocking effective therapeutic avenues.

This research contributes a crucial piece to the ever-expanding puzzle of Alzheimer’s research, underscoring the urgency for continued exploration. As scientists work to identify potential biomarkers and therapeutic targets, the urgency to address the growing incidence of Alzheimer’s disease remains a pressing public health issue. With Texas ranking fourth nationally in Alzheimer’s cases and second in deaths related to the disease, the practical implications of this research are enormous.

For individuals living with Alzheimer’s, the hope for effective interventions is paramount. As research progresses, the findings related to tau vulnerability could serve as a beacon of hope for both clinicians and patients. By leveraging mathematical and computational models, researchers are opening up avenues for innovative treatment modalities that could slow disease progression, ultimately enhancing the quality of life for those affected.

In conclusion, the significant findings from this study represent not just an academic achievement but a pivotal step toward translating scientific research into real-world solutions for Alzheimer’s disease. As the collaboration between mathematics and biology deepens, the potential for breakthroughs in understanding and treating neurodegenerative diseases grows exponentially. In an era of increasing recognition of the challenges posed by Alzheimer’s, the insights drawn from this research provide a much-needed perspective on potential pathways for emerging therapies.

The journey toward unraveling the complexities of Alzheimer’s is ongoing, with continual research efforts aimed at elucidating the intricate relationships within the brain. As we stand at the frontier of neuroscience, the promise of new discoveries offers a ray of hope for countless individuals grappling with this devastating disease.

Subject of Research: Neurobiology and Alzheimer’s Disease
Article Title: Searching for the cellular underpinnings of the selective vulnerability to tauopathic insults in Alzheimer’s disease
News Publication Date: February 7, 2025
Web References: https://www.nature.com/articles/s42003-025-07575-1
References: Communications Biology
Image Credits: Courtesy UTA

Keywords: Alzheimer disease, tau proteins, neurodegeneration, glutamatergic neurons, oligodendrocytes, risk assessment, therapeutic strategies, brain architecture, cognitive decline, neuroprotective mechanisms.